612 related articles for article (PubMed ID: 24572583)
21. Prophylaxis of schizoaffective disorder with lithium or carbamazepine: outcome after long-term follow-up.
Baethge C; Gruschka P; Berghöfer A; Bauer M; Müller-Oerlinghausen B; Bschor T; Smolka MN
J Affect Disord; 2004 Apr; 79(1-3):43-50. PubMed ID: 15023479
[TBL] [Abstract][Full Text] [Related]
22. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
Keck PE; Wilson DR; Strakowski SM; McElroy SL; Kizer DL; Balistreri TM; Holtman HM; DePriest M
J Clin Psychiatry; 1995 Oct; 56(10):466-70. PubMed ID: 7559373
[TBL] [Abstract][Full Text] [Related]
23. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
24. Cognitive functioning and insight in schizophrenia and in schizoaffective disorder.
Birindelli N; Montemagni C; Crivelli B; Bava I; Mancini I; Rocca P
Riv Psichiatr; 2014; 49(2):77-83. PubMed ID: 24770573
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcome of schizoaffective and schizophrenic disorders: a comparative study. I. Definitions, methods, psychopathological and social outcome.
Marneros A; Deister A; Rohde A; Steinmeyer EM; Jünemann H
Eur Arch Psychiatry Neurol Sci; 1989; 238(3):118-25. PubMed ID: 2785920
[TBL] [Abstract][Full Text] [Related]
26. Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia.
Leatherman SM; Liang MH; Krystal JH; Lew RA; Valley D; Thwin SS; Rosenheck RA;
J Nerv Ment Dis; 2014 Jan; 202(1):13-7. PubMed ID: 24375206
[TBL] [Abstract][Full Text] [Related]
27. Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders.
Pinna F; Tusconi M; Bosia M; Cavallaro R; Carpiniello B;
BMC Psychiatry; 2013 Sep; 13():235. PubMed ID: 24294839
[TBL] [Abstract][Full Text] [Related]
28. The impact of duration of untreated psychosis and premorbid functioning on outcome of first inpatient treatment in schizophrenic and schizoaffective patients.
Bottlender R; Sato T; Jäger M; Groll C; Strauss A; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2002 Oct; 252(5):226-31. PubMed ID: 12451464
[TBL] [Abstract][Full Text] [Related]
29. [Affective, schizoaffective and schizophrenic psychoses. A comparative long-term study].
Marneros A; Deister A; Rohde A
Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1991; 65():1-454. PubMed ID: 1791861
[TBL] [Abstract][Full Text] [Related]
30. [Schizophrenic disorders--does cognitive dysfunction relate to characteristics of course and psychopathology of the illness?].
Wciórka J; Bembenek A; Hintze B; Kühn-Dymecka A
Psychiatr Pol; 2006; 40(5):867-84. PubMed ID: 17217232
[TBL] [Abstract][Full Text] [Related]
31. [Tunisian mothers' beliefs about their child's first psychotic episode].
Bourgou S; Halayem S; Bouden A; Halayem MB
Encephale; 2012 Dec; 38(6):473-9. PubMed ID: 23200613
[TBL] [Abstract][Full Text] [Related]
32. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
[TBL] [Abstract][Full Text] [Related]
33. [Generic quetiapine in the treatment of acute schizophrenia and schizoaffective disorder].
György B; Robert K; László C; Andrea J;
Neuropsychopharmacol Hung; 2008 Dec; 10(5):293-303. PubMed ID: 19419015
[TBL] [Abstract][Full Text] [Related]
34. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia.
Ho BC; Andreasen NC; Flaum M; Nopoulos P; Miller D
Am J Psychiatry; 2000 May; 157(5):808-15. PubMed ID: 10784476
[TBL] [Abstract][Full Text] [Related]
35. Duration of psychosis and outcome in first-episode schizophrenia.
Loebel AD; Lieberman JA; Alvir JM; Mayerhoff DI; Geisler SH; Szymanski SR
Am J Psychiatry; 1992 Sep; 149(9):1183-8. PubMed ID: 1503130
[TBL] [Abstract][Full Text] [Related]
36. The influence of gender on clinical and social characteristics of patients at psychosis onset: A report from the Psychosis Incident Cohort Outcome Study (PICOS).
Bertani M; Lasalvia A; Bonetto C; Tosato S; Cristofalo D; Bissoli S; De Santi K; Mazzoncini R; Lazzarotto L; Santi M; Sale A; Scalabrin D; Abate M; Tansella M; Rugger M
Psychol Med; 2012 Apr; 42(4):769-80. PubMed ID: 21995856
[TBL] [Abstract][Full Text] [Related]
37. Psychopathological and demographic characteristics of hallucinating patients with schizophrenia and schizoaffective disorder: an analysis based on AMDP data.
Baethge C; Jänner M; Gaebel W; Malevani J
Eur Arch Psychiatry Clin Neurosci; 2017 Jun; 267(4):295-301. PubMed ID: 27752826
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of quality of life for patients with schizophrenic and schizoaffective disorders related to the use of antipsychotic therapy.
Golubovic B; Misic-Pavkov G; Gajic Z; Ivanovic-Kovacevic S
Med Arh; 2010; 64(1):37-40. PubMed ID: 20422824
[TBL] [Abstract][Full Text] [Related]
39. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
40. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
